Baxfendy has been recommended for the treatment of adults with arterial hypertension that is not adequately controlled by at least two antihypertensive medicines.
If approved, it will become the first aldosterone synthase inhibitor (ASI) on the EU market. Baxfendy works by inhibiting the production of aldosterone, a hormone that plays an important role in regulating blood pressure.